Marble Harbor Investment Counsel LLC Has $1.86 Million Holdings in DexCom, Inc. (DXCM)

Marble Harbor Investment Counsel LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 36.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,940 shares of the medical device company’s stock after purchasing an additional 10,150 shares during the period. Marble Harbor Investment Counsel LLC’s holdings in DexCom were worth $1,856,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the business. Bbva Compass Bancshares Inc. increased its stake in DexCom by 1.9% in the 2nd quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock worth $268,000 after purchasing an additional 69 shares during the period. Public Employees Retirement Association of Colorado increased its stake in DexCom by 0.4% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock worth $1,362,000 after purchasing an additional 83 shares during the period. World Asset Management Inc increased its stake in DexCom by 4.1% in the 2nd quarter. World Asset Management Inc now owns 3,901 shares of the medical device company’s stock worth $285,000 after purchasing an additional 155 shares during the period. Wedbush Securities Inc. increased its stake in DexCom by 5.0% in the 2nd quarter. Wedbush Securities Inc. now owns 4,200 shares of the medical device company’s stock worth $307,000 after purchasing an additional 200 shares during the period. Finally, Rathbone Brothers plc increased its stake in DexCom by 5.3% in the 2nd quarter. Rathbone Brothers plc now owns 4,000 shares of the medical device company’s stock worth $293,000 after purchasing an additional 200 shares during the period.

ILLEGAL ACTIVITY WARNING: “Marble Harbor Investment Counsel LLC Has $1.86 Million Holdings in DexCom, Inc. (DXCM)” was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.truebluetribune.com/2017/11/16/marble-harbor-investment-counsel-llc-has-1-86-million-holdings-in-dexcom-inc-dxcm.html.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $69.81, for a total transaction of $101,224.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steven R. Altman acquired 10,000 shares of DexCom stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average price of $49.61 per share, with a total value of $496,100.00. Following the transaction, the director now owns 4,353 shares of the company’s stock, valued at approximately $215,952.33. The disclosure for this purchase can be found here. Insiders sold 13,964 shares of company stock valued at $948,039 in the last 90 days. Company insiders own 1.70% of the company’s stock.

DXCM has been the topic of a number of recent analyst reports. Northland Securities lowered DexCom from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $85.00 to $60.00 in a research report on Thursday, September 28th. Wedbush restated a “buy” rating and set a $76.00 price target on shares of DexCom in a research report on Wednesday, October 4th. Robert W. Baird restated a “hold” rating and set a $79.00 price target on shares of DexCom in a research report on Sunday, September 10th. Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Finally, TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $70.69.

DexCom, Inc. (NASDAQ DXCM) traded up $0.45 during mid-day trading on Thursday, hitting $52.00. The stock had a trading volume of 1,352,600 shares, compared to its average volume of 1,433,743. DexCom, Inc. has a 52-week low of $42.62 and a 52-week high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply